拉米夫定对HBV-DNA及HBeAg的影响研究  

Study of influence of Lamivudine on HBV-DNA and HBeAg

作　　者：孙爱秀[1] 周书生[1] 

机构地区：[1]山东省昌邑市人民医院感染科,山东昌邑261300

出　　处：《中国医药导报》2012年第22期157-158,共2页China Medical Herald

摘　　要：目的研究拉米夫定对乙型病毒性肝炎患者机体内HBV-DNA病毒含量及HBeAg的影响。方法选择我院87例拉米夫定治疗的乙肝患者为实验组,并以同期56例行一般护肝治疗的乙肝患者为对照组,研究两组不同治疗阶段HBV-DNA病毒载量及HBeAg的变化特点。结果两组治疗前HBV-DNA平均对数值经比较,差异无统计学意义(P>0.05);治疗3、6个月及1年两组HBV-DNA平均对数值比较,差异均有高度统计学意义(P<0.01);实验组HBV-DNA、HBeAg不同时期阳性率差异有高度统计学意义(P<0.01),对照组HBV-DNA、HBeAg不同时期阳性率差异无统计学意义(P>0.05)。结论拉米夫定对慢性乙型肝炎有很好的临床疗效。Objective To study the influence of Lamivudine on the HBV-DNA virus content and HBeAg in patients with viral B hepatitis. Methods A total of 87 patients with hepatitis B receiving Lamivudine treatment in our hospital were selected as the experiment group and 56 contemporary patients with hepatitis B receiving common live protection treatment were selected as the control group. The changes of HBV-DNA viral load and HBeAg in different treatment stages of the two groups were studied. Results The average log values of HBV-DNA before treatment between the two groups were not significantly different （P 〉 0.05）; the average log values of HBV-DNA 3, 6 months and 1 year after treatment were all significantly different between the two groups （P 〈 0.01）. The positive rates of HBV-DNA and HBeAg in different stages of the experiment group were significantly different （P 〈 0.01）; the positive rates of HBV-DNA and HBeAg in different stages of the control group were not significantly different （P 〉 0.05）. Conclusion Lamivudine has good clinical curative effects in the treatment of chronic hepatitis B.

关 键 词：慢性乙型肝炎 拉米夫定 HBV—DNA E抗原 

分 类 号：R512.62[医药卫生—内科学]